Upcoming Events
  1. TACT Board Teleconference (closed)

    August 28 - August 29
  2. ESMO 2017 Congress, Madrid Spain

    September 8 - September 12
  3. ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC

    September 22 @ 12:00 pm - September 23 @ 5:00 pm UTC+10
  4. TACT General Assembly (closed), Yokohama Japan

    October 15
  5. 18th WCLC, Yokohama Japan

    October 15 - October 18

Who’s Who

Emily Stone, Respiratory Medicine Representative – MAC

Please tell us a little about yourself and how you came to be involved with the ALTG

I’m a respiratory physician at St Vincents hospital in Sydney.  I started our MDT in 2006 and have developed it since then. I became involved in the ALTG through colleagues in respiratory medicine and oncology from around Australia.

What is it about being a member of the MAC that you find most interesting?

It gives me an opportunity to share ideas and views with clinicians and researchers from around the country and gives me insight into the full range of issues that are important for lung cancer patients.  It also gives me contacts across a range of areas of expertise something that has helped me in both clinical medicine and in research.

How would you like to see the ALTG develop over time?

I see the ALTG developing its leadership role in clinical lung cancer research so that new and established researchers can turn to the ALTG for a range of resources – access to colleagues, mentorship and advice and research opportunities.

 

Anna Nowak, Mesothelioma SAC Subgroup Co-Chair

Please tell us a little about yourself and how you came to be involved with the ALTG

I was an inaugural member of the ALTG, which was formed at a meeting in Sydney whilst I was a postdoctoral fellow at the NHMRC Clinical Trials Centre. From memory Martin Stockler carted me along to the first meeting, so I guess that was in 2003.

However I had already done a PhD in malignant mesothelioma and subsequent work on quality of life analysis and tumour measurement in this disease, so the ALTG was an obvious vehicle for future trials in this rare and relatively neglected thoracic cancer. As I have continued to work in mesothelioma in the laboratory and clinical trials, the ALTG has become an important collaborative vehicle for this work.

What is it about being a member of the SAC that you find most interesting?

Working collaboratively with colleagues to refine a clinical trial idea is the most interesting and enjoyable part of being a MAC/SAC member. One person can never think of everything important. Everyone has input into the development of a new clinical trial, the teamwork is fantastic.

How would you like to see the ALTG develop over time?

Being the co-chair of the mesothelioma subgroup, of course I’d like to see the ALTG have an open mesothelioma trial at all times. The DREAM clinical trial is the second ALTG mesothelioma trial, but we haven’t had a mesothelioma trial open through the ALTG for a few years, since the close of B2P2M2. I’d also like to see the ALTG develop more supportive care trials for thoracic cancers.